Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases

Inclusion Criteria:

* Histopathologically confirmed complete resection (R0) of liver metastases from colorectal adenocarcinoma
* Age ≥18 years
* ECOG performance status ≤ 2
* Patient was informed, has read and understood the patient information / informed consent form and has given written informed consent

Exclusion Criteria:

* Extra-hepatic distant metastases or locally recurrent disease at time of enrolment
* Neoadjuvant chemotherapy of liver metastases prior to surgery
* Any anticancer chemotherapy within 4 weeks prior to study entry
* Start of Oxaliplatin-based chemotherapy within 9 months prior to study entry
* Any biological anticancer therapy or immunotherapy within 4 weeks prior to study entry
* Any radiotherapy or radio frequency ablation (RFA) to the liver prior to surgery
* Treatment with any investigational product within a time range of 4-5 half-lives (t½) prior to study entry
* Acute or chronic pancreatitis or history of alcohol induced pancreatitis
* Liver cirrhosis, acute hepatitis or chronic hepatic disease
* Any unresolved complications from prior surgery
* Persistent neuropathy
* History of other malignancy within 5 years prior to study start, with the exception of basal cell carcinoma of the skin, carcinoma in situ of the cervix and Ductal Carcinoma in Situ (DCIS)
* History of inflammatory bowel disease
* Active severe infection, any other concurrent disease or medical condition that is deemed to interfere with the conduct of the study as judged by the investigator
* Use of immune-suppressive agents such as the regular use of systemic corticosteroids
* HIV positivity
* Known hypersensitivity or intolerability to immunoglobulins in general, other recombinant human or humanized antibodies, Folinic Acid, 5-Fluorouracil, Oxaliplatin or a component of the study drug formulations, known dihydropyrimidine dehydrogenase (DPD) deficiency
* Pregnant or nursing women
* Women of childbearing potential or male patients not willing to use an effective form of contraception during treatment phase of the study and at least 6 months thereafter
* Not willing or incapable to comply with all study visits and assessments
* Placed into an institution due to juridical or regulatory ruling